Cargando…

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer’s Disease

BACKGROUND: Down syndrome (DS) is a genetic form of Alzheimer’s disease (AD) with a high prevalence of obstructive sleep apnea (OSA). These characteristics place the DS population as an optimal model to study the relationship between sleep and AD and to design clinical trials of preventive sleep the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giménez, Sandra, Farre, Ariadna, Morente, Fátima, Videla, Laura, Gutiérrez, Marta, Clos, Susana, Fernández, Ana, Blanco, Marta, Altuna, Miren, Pegueroles, Jordi, Asensio, Amparo, Benejam, Bessy, Batista, Mar, Barroeta, Isabel, Fortuna, Ana, Fortea, Juan, Mayos, Mercedes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005794/ https://www.ncbi.nlm.nih.gov/pubmed/35431793 http://dx.doi.org/10.3389/fnins.2022.838412

Ejemplares similares

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
por: Benejam, Bessy, et al.
Publicado: (2022)

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
por: Benejam, Bessy, et al.
Publicado: (2020)

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
por: Videla, Laura, et al.
Publicado: (2022)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
por: Belbin, Olivia, et al.
Publicado: (2020)

Evaluation of biochemical and hematological parameters in adults with Down syndrome
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
por: Iulita, Maria Florencia, et al.
Publicado: (2022)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity
por: Altuna, Miren, et al.
Publicado: (2021)

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
por: Bejanin, Alexandre, et al.
Publicado: (2021)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
por: Pegueroles, Jordi, et al.
Publicado: (2020)

Sleep Disorders in Adults with Down Syndrome
por: Giménez, Sandra, et al.
Publicado: (2021)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2021)

Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2023)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
por: Moreau, Manon, et al.
Publicado: (2022)

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders
por: Alcolea, Daniel, et al.
Publicado: (2019)

Cerebral vasoreactivity in response to a head-of-bed position change is altered in patients with moderate and severe obstructive sleep apnea
por: Gregori-Pla, Clara, et al.
Publicado: (2018)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
por: Altuna, Miren, et al.
Publicado: (2022)

Manejo de la apnea obstructiva del sueño en atención primaria en relación con el nuevo documento de consenso internacional
por: Peñacoba Toribio, Patricia, et al.
Publicado: (2021)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders
por: Delaby, C., et al.
Publicado: (2020)

Counterfactual Reasoning Deficits in Schizophrenia Patients
por: Contreras, Fernando, et al.
Publicado: (2016)

Patients with schizophrenia activate behavioural intentions facilitated by counterfactual reasoning
por: Contreras, Fernando, et al.
Publicado: (2017)

Characterization of the microvascular cerebral blood flow response to obstructive apneic events during night sleep
por: Zirak, Peyman, et al.
Publicado: (2018)

How does obstructive sleep apnea alter cerebral hemodynamics?
por: Gregori-Pla, Clara, et al.
Publicado: (2023)

New Community and Sociohealth Challenges Arising from the Early Diagnosis of Mild Cognitive Impairment (MCI)
por: López, Carolina, et al.
Publicado: (2023)

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
por: de Sola, Susana, et al.
Publicado: (2015)

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies
por: Querol-Vilaseca, Marta, et al.
Publicado: (2017)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Nutrition Claims Frequency and Compliance in a Food Sample of the Spanish Market: The BADALI Study
por: Ropero, Ana B., et al.
Publicado: (2020)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study
por: Pegueroles, Jordi, et al.
Publicado: (2018)

Multiple adverse drug reactions and genetic polymorphism testing: A case report with negative result
por: Arellano, Ana Lucía, et al.
Publicado: (2017)

Effect of fibrous diet and vitamin C inclusion on uniformity, carcass traits, skeletal strength, and behavior of broiler breeder pullets
por: Asensio, X., et al.
Publicado: (2020)

Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review
por: Altuna, Miren, et al.
Publicado: (2022)

Evaluation of Happy Sport, an Emotional Education Program for Assertive Conflict Resolution in Sports
por: Ros-Morente, Agnès, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e0ojpns5190udt8r9peeqs2lg9